Deprescribing Anticholinergic and Sedative Medications, Physical Function
Conditions
Brief summary
Medications with sedative or anticholinergic effects such as antidepressants, benzodiazepines, or opioids have been associated with impaired cognitive and physical function. They are referred to as potentially inappropriate medications or medications that are best avoided by older adults. The accumulated evidence has now shifted the clinical and research focus to evaluating the who, what, and how of the best way to deprescribe (i.e., dose reduction or cessation of these medications). The Drug Burden Index (DBI) allows researchers and clinicians to quantify the cumulative burden of anticholinergic and sedative medications in each patient. Deprescribing these medications is a complex health intervention based on trade-offs between their clinical benefits (e.g., symptom management and prevention of diseases) and their adverse drug events to improve physical and cognitive function. Existing physical function performance metrics, such as gait speed captured in the clinic, are often non-specific and do not reflect real-life performance. Innovative mobility metrics are required to better understand specific deficits with age and disease and the effects of medications on these deficits. The goal of this project is to better characterize the impact of reducing the anticholinergic and sedative medication burden on physical function in older adults by novel mobility metrics in lab and real-life environments. A prospective, longitudinal cohort of 182 community-dwelling older adults (≥ 65 years) with a DBI of ≥ 1 will be completed. Using a quasi-experimental design, recruited patients will undergo a medication deprescribing plan, as part of usual clinical care, that includes three gradual changes to their medication regimen resulting in three DBI levels. At each DBI level, physical function mobility including dual-task tests) will be assessed in the lab with wearable sensors during validated clinical tests such as the Short Physical Performance Battery. Objective balance and mobility metrics (e.g., sway area and frequency, stride length) will be extracted. Physical function will also be assessed continuously in the patient's real-life environment from recruitment to the last lab visit, using wearable (Apple Watch® with ankle inertial measurement unit) and environmental sensors. Cognition will be measured using the Montreal Cognitive Assessment, Trail Making Test Part A & B, and Digit Symbol Substitution Test.
Interventions
DRUGDeprescribing anticholinergic and sedative mediications
Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
Sponsors
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 65 years and older * community-dwelling * Drug Burden Index score of ≥ 1 * Agree with a deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5.
Exclusion criteria
* Dementia * Need of a walker as a mobility assistive device * Unstable medical condition (≥ 1 unplanned hospitalization or ≥ 2 emergency department visits in the past month).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in gait capacity measured in the lab from baseline to study completion | Through study completion, an average of 4 months. | Gait speed (m/s) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in functional limitations and disability from baseline to study completion | Through study completion, an average of 4 months. | Late-Life Function and Disability Instrument (Late-Life FDI), |
| Change in caregiver report of the patients' functional status from baseline to study completion | Through study completion, an average of 4 months. | Older Adults Resources and Services (OARS) Multidimensional Functional Assessment Questionnaire adapted for the caregiver. |
| Change in falls and near falls from baseline to study completion | Through study completion, an average of 4 months. | Falls nand near falls recorded by patient diary |
| Change in gait performance measured in real-life settings from baseline to study completion | Through study completion, an average of 4 months. | Gait activity (number of steps) |
| Change in Montreal Cognitive Assessment (MoCA) from baseline to study completion | Through study completion, an average of 4 months. | Full version |
| Change in Trail Making Test (TMT) from baseline to study completion | Through study completion, an average of 4 months. | Part A & B |
| Change in Digit Symbol Substitution Test from baseline to study completion | Through study completion, an average of 4 months. | DSST |
| Adverse drug events and adverse drug withdrawal events | Continuous during the deprescribing process | Adverse anticholinergic and sedative effects from G-MEDSS |
Countries
Canada
Contacts
Primary ContactMarilyn Tousignant, MSc
Outcome results
None listed